Reading room

Terapia September 2021 NR 9 ( 404 )

Heart failure

Editor of the issue: prof. dr hab. n. med. Krzysztof J. Filipiak, prof. dr hab. n. med. Marek Postuła

Contents:

Heart failure 2021 ‒ most important changes in European guidelines

    Authors:
  • prof. dr hab. n. med. Krzysztof J. Filipiak
  • prof. dr hab. n. med. Marek Postuła
Keywords: heart failure, ESC guidelines, guidelinesʼ changes

Diagnosis and classification of heart failure for a practicing physician

    Authors:
  • dr n. med. Anna Ścibisz
  • dr hab. n. med. Agnieszka Kapłon-Cieślicka
Keywords: heart failure, guidelines, ejection fraction, natriuretic peptides

Beta-blockers and ivabradine ‒ the basis of heart rate control in case of heart failure

    Authors:
  • prof. dr hab. n. med. Krzysztof J. Filipiak
  • Monika Romańczyk
  • lek. Stanisław Surma
Keywords: heart failure, arrhytmias, beta blockers; ivabradine

Renin-angiotensin-aldosterone system inhibitors in heart failure: ACE inhibitors, angiotensin receptor blockers or ARNI?

    Authors:
  • lek. Ewa Wojciechowska
  • dr n. med. Piotr Gryglas
  • dr hab. n. med. Agnieszka Kapłon-Cieślicka
Keywords: heart failure, angiotensin-converting-enzyme inhibitor, angiotensin receptor blocker, neprilysin inhibitor, hypotension, hyperkalemia, renal failure, creatinine

Aldosterone antagonists ‒ which one to choose for heart failure?

    Authors:
  • lek. Stanisław Surma
  • Monika Romańczyk
  • prof. dr hab. n. med. Krzysztof J. Filipiak
Keywords: aldosterone antagonists, spironolactone, eplerenone, finerenone, heart failure

SGLT2 inhibitors ‒ new drugs in heart failure ‒ should they be first-line drugs?

    Authors:
  • lek. Joanna Jarosz-Popek
  • lek. Pamela Czajka
  • lek. Anna Nowak
  • lek. Marta Wolska
  • prof. dr hab. n. med. Marek Postuła
Keywords: sodium glucose cotransporter-2 inhibitors, empagliflozin, dapagliflozin, canagliflozin, heart failure

SGLT2 inhibitors ‒ from treating heart failure to prevention of diabetes

    Authors:
  • lek. Anna Nowak
  • lek. Marta Wolska
  • lek. Joanna Jarosz-Popek
  • prof. dr hab. n. med. Marek Postuła
Keywords: type 2 diabetes mellitus, heart failure, SGLT2 inhibitors, empagliflozin, dapagliflozin, sotagliflozin, canagliflozin

SGLT2 inhibitors - suitable treatment for nephropathy associated with heart failure?

    Authors:
  • lek. Marta Wolska
  • lek. Pamela Czajka
  • lek. Joanna Jarosz-Popek
  • lek. Anna Nowak
  • prof. dr hab. n. med. Marek Postuła
Keywords: sodium-glucose cotransporter-2 inhibitors, SGLT2 inhibitors, heart failure, nephroprotection, cardioprotection, chronic kidney disease

Digoxin and new inotropic agents in heart failure ‒ the contemporary place in therapy

    Authors:
  • lek. Piotr Szwed
  • dr n. med. Aleksandra Gąsecka
  • prof. dr hab. n. med. Krzysztof J. Filipiak
Keywords: heart failure, inotropic drugs, digoxin, catecholamines, milrinone, levosimendan, omecamtiv mekabril

Underestimated therapies: coenzyme Q10 in heart failure

    Authors:
  • lek. Stanisław Surma
  • prof. dr hab. n. med. Krzysztof J. Filipiak
Keywords: coenzyme Q10, heart failure